APA (7th ed.) Citation

Wu, D., Liu, J., Paragas, E. M., Yadav, J., Aliwarga, T., Heimbach, T., & Escotet-Espinoza, M. S. (2025). Assessing and mitigating pH-mediated DDI risks in drug development – formulation approaches and clinical considerations. Drug Metabolism Reviews, 57(3), 291. https://doi.org/10.1080/03602532.2024.2345632

Chicago Style (17th ed.) Citation

Wu, Di, Jiaying Liu, Erickson M. Paragas, Jaydeep Yadav, Theresa Aliwarga, Tycho Heimbach, and M. Sebastian Escotet-Espinoza. "Assessing and Mitigating PH-mediated DDI Risks in Drug Development – Formulation Approaches and Clinical Considerations." Drug Metabolism Reviews 57, no. 3 (2025): 291. https://doi.org/10.1080/03602532.2024.2345632.

MLA (9th ed.) Citation

Wu, Di, et al. "Assessing and Mitigating PH-mediated DDI Risks in Drug Development – Formulation Approaches and Clinical Considerations." Drug Metabolism Reviews, vol. 57, no. 3, 2025, p. 291, https://doi.org/10.1080/03602532.2024.2345632.